Search results
Decoding Amgen Inc (AMGN): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 1 day agoThreats Pricing Pressures and Healthcare Reforms: Amgen Inc operates in an environment where pricing pressures from payers and government healthcare...
Amgen Soars as CEO Touts Experimental Obesity Drug Progress
Bloomberg via Yahoo Finance· 2 days ago(Bloomberg) -- Amgen Inc.’s shares soared after its chief executive officer said he was “very...
Amgen shares soar on obesity drug optimism
Proactive Investors· 2 days agoAmgen Inc (NASDAQ:AMGN, ETR:AMG) shares gained almost 13% at about $314 in early trade on Friday after the drugmaker said it was “very encouraged” by...
...Stock Adds Good Weight After CEO's Update On Experimental Drug Rivaling Ozempic, Nixing Oral...
Benzinga· 2 days agoAmgen, Inc. AMGN shares rallied over 14% in Thursday’s after-hours trading after the biopharma...
Amgen 'very encouraged' by data from weight-loss-drug trial, as stock jumps
Morningstar· 2 days agoShares of Amgen Inc. soared in premarket trading Friday, after the drug manufacturer posted adjusted earnings above expectations and ...
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
AOL· 5 days agoGeneric and biosimilar manufacturer Sandoz AG (OTC:SDZNY) (OTC:SDZXF) reached an agreement on Tuesday with Amgen Inc (NASDAQ:AMGN) to resolve all patent ...
Amgen 'encouraged' by weight-loss drug interim data, shares jump
Reuters· 3 days ago, opens new tab on Thursday said it was very encouraged after completing an interim analysis of its...
Amgen, Sandoz Settle Clash Over Biosimilars of Blockbuster Drugs
Bloomberg Law· 6 days agoand Sandoz Group AG settled a patent-infringement lawsuit over biosimilar versions of Amgen’s Prolia and Xgeva bone-strengthening treatments, according to a New Jersey federal judge’s order.
Obesity drug rivals aim to unseat Zepbound, Ozempic - Indianapolis Business Journal
Indianapolis Business Journal· 2 days agoInsatiable demand for weight-loss drugs has made the market so feverish that any positive mention of...
Analyst Report: Amgen Inc.
Morningstar Research via Yahoo Finance· 2 days agoAmgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx ...
